GlassScriptPhysician profile
Jeffrey Wilson
NPI 1922108745
$4,787.62
in general payments reported to CMS, 2019-2025
31 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.76 · 2020: $351 · 2021: $1,707 · 2022: $679 · 2023: $1,543 · 2024: $242 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,012.16 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $914.00 | 2020-2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $646.11 | 2020-2024 | Nucala, Trelegy Ellipta |
| Lilly USA, LLC | $350.07 | 2020-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $303.10 | 2020-2022 | |
| Abbott Laboratories | $222.01 | 2022-2023 | Amplatzer Talisman, Freestyle Libre 3 |
| Amarin Pharma, INC. | $166.31 | 2021 | |
| Amgen INC. | $146.66 | 2020-2023 | Prolia, Evenity, Repatha |
| Paratek Pharmaceuticals, INC. | $125.00 | 2023 | Nuzyra |
| Esperion Therapeutics, INC. | $82.55 | 2021 | |
| Sanofi-Aventis U.S. LLC | $79.89 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $72.24 | 2020-2022 | |
| Pfizer INC. | $69.02 | 2021 | |
| Abbvie INC. | $63.41 | 2022-2023 | Vraylar |
| Novartis Pharmaceuticals Corporation | $50.27 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $47.72 | 2022 | |
| Genentech USA, INC. | $46.16 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.76 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.82 | 2020 | |
| Merck Sharp & Dohme LLC | $39.73 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.03 | 2022 | |
| Nestle Healthcare Nutrition INC. | $38.24 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $33.86 | 2021 | |
| Jazz Pharmaceuticals INC. | $25.17 | 2020 | |
| Medartis INC. | $24.33 | 2025 | Aptus |
| Hologic Sales and Service, LLC | $22.43 | 2023 | Thinprep 2000 Processor, Aptima |
| Exact Sciences Corporation | $19.28 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.73 | 2021 | |
| Pharming Healthcare, INC. | $17.52 | 2021 | |
| Clarus Therapeutics INC. | $16.04 | 2021 | |
| Antares Pharma, INC. | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.